Pancuronium pandemonium as doctors slam Hospira for execution injections
This article was originally published in Scrip
An open letter published in the Lancet has criticised Hospira for its handling of the use of its muscle relaxant pancuronium bromide in executions in the US. However, Lundbeck, which faced a similar issue with its drug pentobarbital (Nembutal) for acute convulsive disorders, has emerged with its reputation intact. The letter praises the firm for its "truly exemplary" response to the situation after it tightened distribution of the drug.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.